![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1701964
µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ µð¹ÙÀ̽º ½ÃÀå : ¸ð´ÏÅ͸µ À¯Çüº°, Á¦Ç°º°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)Digital Patient Monitoring Devices Market Report by Monitoring Type, Product, End User (Hospitals, Home Settings, Ambulatory Surgical Centers ), and Region 2025-2033 |
¼¼°èÀÇ µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ µð¹ÙÀ̽º ½ÃÀå ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 1,541¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2033³â±îÁö 7,737¾ï ´Þ·¯¿¡ ´ÞÇϸç, 2025-2033³â¿¡ 19.6%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ Áõ°¡, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀ¸·ÎÀÇ À̵¿, ±â¼úÀÇ Áøº¸°¡ ÁÖ·Î µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ±â±â´Â Ç÷¾Ð, ½É¹Ú¼ö, ü¿Â, ¸Æ¹Ú¼ö, Ç÷Áß »ê¼ÒÆ÷ȵµ(SPO2) µî ȯÀÚÀÇ ¹ÙÀÌÅ» ÆÄ¶ó¹ÌÅ͸¦ ¸ð´ÏÅ͸µÇÏ´Â ÀüÀÚ±â±â¸¦ ¸»ÇÕ´Ï´Ù. ¼Òº¯·®, üÁß, ü¿Â, È£Èí, ½ÉÀå, ½Å°æ ¸ð´ÏÅ͸µ, ¿ø°Ý ȯÀÚ µîÀº ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ±â±âÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ±â±â´Â Áúº´À¸·Î ÀÎÇÑ ÇÕº´Áõ Áö¿¬ ¹× ¿¹¹æ, ÀÛ¾÷·® °¨¼Ò, ½Ã°£ Àý¾à, ¿À·ù °¨¼Ò, Ä¿¹Â´ÏÄÉÀÌ¼Ç °³¼±, ȯÀÚ Âü¿© ¹× ÅëÁ¦·Â Çâ»ó, ¾ÈÀü¼º Çâ»óÀ» µ½½À´Ï´Ù. ±× °á°ú º´¿ø, Áø·á¼Ò, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÀçÅÃÀÇ·á ÇöÀå¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
ÇコÄÉ¾î »ê¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå, ¿¬¼Ó ¸ð´ÏÅ͸µ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, °íÇ÷¾Ð, õ½Ä, Ç÷¾Ð, ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. À̿ʹ º°µµ·Î, ÀϹÝÀûÀÎ »ý¸®Àû ÆÄ¶ó¹ÌÅÍÀÇ ½Å¼ÓÇÑ ºÐ¼®À» Áö¿øÇÏ´Â ½º¸¶Æ® µðÁöÅРȯÀÚ ¸ð´ÏÅ͸µ ±â±âÀÇ µµÀÔ°ú °°Àº ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀÌ ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ Ç÷´ç ¼öÄ¡¸¦ ½Ç½Ã°£À¸·Î ÃßÀûÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅÍ¿Í °°Àº ´Ù¾çÇÑ ¼¾¼ ±â¹Ý ¿þ¾î·¯ºí ¸ð´ÏÅ͸µ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °¡Á¬Àº ±â·ÏµÈ °Ç° µ¥ÀÌÅ͸¦ ´Ù¸¥ ÅëÇÕ ¸ð´ÏÅ͸µ Àåºñ¸¦ ÅëÇØ ÀÇ·áÁø¿¡°Ô ÀüÀÚÀûÀ¸·Î Àü¼ÛÇÕ´Ï´Ù. ±âŸ ³ëÀÎ Àα¸ Áõ°¡, ¼ÒºñÀÚÀÇ ÁöÃâ ´É·Â Áõ°¡, Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ °©ÀÛ½º·¯¿î ¹ß»ýÀ¸·Î ÀÎÇÑ ÀçÅà °£È£ ÇöÀå¿¡¼ÀÇ Á¦Ç° ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
The global digital patient monitoring devices market size reached USD 154.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 773.7 Billion by 2033, exhibiting a growth rate (CAGR) of 19.6% during 2025-2033. The rising prevalence of chronic diseases, shift towards remote patient monitoring, and technological advancements are primarily driving the digital patient monitoring market growth.
Digital patient monitoring devices refer to electronic instruments intended to monitor the patient's vital parameters, such as blood pressure, heart rate, temperature, pulse rate, and blood oxygen saturation levels (SPO2). Urine output, weight, temperature, respiratory, cardiac, neuromonitoring and remote patient are some of the commonly available types of digital patient monitoring devices. Digital patient monitoring devices assist in delaying and preventing complications from the disease, reducing workload, saving time, reducing errors, improving communication, increasing patient engagement and control, and enhancing safety. As a result, they are extensively used in hospitals, clinics, ambulatory surgical centers (ASC), and home care settings.
Significant growth in the healthcare industry, the rising demand for continuous monitoring devices, and the increasing prevalence of chronic medical ailments, such as hypertension, asthma, blood pressure and diabetes, represent key factors majorly driving the digital patient monitoring devices market growth. Apart from this, various advancements in technology, such as the introduction of smart digital patient monitoring devices that assist in the quick analysis of common physiological parameters, are providing an impetus to the market growth. Additionally, the increasing demand for various sensor-based wearable monitoring devices, such as continuous glucose monitors that help in tracking the patient's blood sugar levels on a real-time basis, is favoring the market growth. These gadgets transmit the recorded heath data electronically to medical practitioners through another integrated monitoring device, which, in turn, enables them to constantly keep a check on patient's health, thus reducing the instances of developing serious illnesses. Other factors, including the increasing geriatric population, rising expenditure capacity of consumers, and widespread product demand across in-home care settings due to the sudden outbreak of coronavirus disease (COVID-19), are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AT&T Inc., Athenahealth Inc., F. Hoffmann-La Roche AG, General Electric Company, Hill-Rom Holdings Inc. (Baxter International Inc.), Johnson & Johnson, Koninklijke Philips N.V, Medtronic plc, Nihon Kohden Corporation, OMRON Corporation and ResMed.